141 related articles for article (PubMed ID: 31523585)
21. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
22. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.
Iwama E; Okamoto I; Harada T; Takayama K; Nakanishi Y
Onco Targets Ther; 2014; 7():375-85. PubMed ID: 24623980
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
24. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
[TBL] [Abstract][Full Text] [Related]
25. Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications.
Hainsworth JD; Anthony Greco F
Drugs Real World Outcomes; 2016 Mar; 3(1):115-120. PubMed ID: 27747807
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
29. ALK-rearrangements and testing methods in non-small cell lung cancer: a review.
Shackelford RE; Vora M; Mayhall K; Cotelingam J
Genes Cancer; 2014 Apr; 5(1-2):1-14. PubMed ID: 24955213
[TBL] [Abstract][Full Text] [Related]
30. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma.
Ashish S; Rodriguez RR; Sethi P; Yu F; Raj M
Cureus; 2022 Oct; 14(10):e29922. PubMed ID: 36348885
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Patient With Lung Adenocarcinoma With
Gao P; Tang K; Hao Y; Li W; Lv X; Li D; Jia Y
Front Oncol; 2022; 12():762338. PubMed ID: 35280798
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.
Shackelford RE; Ansari JM; Wei EX; Alexander JS; Cotelingam J
Pharmacogenomics; 2017 Aug; 18(12):1179-1192. PubMed ID: 28745554
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.
Miao Y; Zhu S; Li H; Zou J; Zhu Q; Lv T; Song Y
J Thorac Dis; 2017 Oct; 9(10):3927-3937. PubMed ID: 29268403
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma.
Yang S; Yang L; Wu Y; Zhang C; Wang S; Ma N; Wang L; Wang Q
Ann Transl Med; 2020 Oct; 8(20):1307. PubMed ID: 33209887
[TBL] [Abstract][Full Text] [Related]
38. Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.
Jazieh AR; Gaafar R; Errihani H; Jaafar H; Al Dayel F; Bahnassy AA; El Kadi H; Abdallah MM; Zaatari G
JCO Glob Oncol; 2021 Sep; 7():1556-1563. PubMed ID: 34788123
[TBL] [Abstract][Full Text] [Related]
39. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
[TBL] [Abstract][Full Text] [Related]
40. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]